Tivic Health Systems, Inc. (TIVC) Q2 2024 Earnings Call Transcript Summary
Tivic Health Systems, Inc. (TIVC) Q2 2024 Earnings Call Transcript Summary
Net loss for Q2 2024 was $1.3 million, improving from a $2.1 million loss in 2023.The following is a summary of the Tivic Health Systems, Inc. (TIVC) Q2 2024 Earnings Call Transcript:
以下是Tivic Health Systems, Inc.（TIVC）2024年第二季度業績會交流摘要：
Financial Performance:
金融業績：
Tivic Health reported lower ClearUP revenues for Q2 2024, totaling $140,000, a 12% decrease year-over-year, primarily due to a 27% decrease in unit sales offset by a 20% increase in the per-unit average sale price.
Gross profits for the three and six months ended June 30 were $30,000 and $197,000 respectively, showing an improvement in gross margin from 32% to 42%.
Net loss for Q2 2024 was $1.3 million, improving from a $2.1 million loss in 2023.
The company achieved a cash position of $3.7 million as of June 30, 2024, compared to $3.4 million at the end of 2023.
Tivic Health報告了2024年第二季度ClearUP收入下降的情況，總額爲140,000美元，同比下降12％，主要是因爲銷售數量下降27％，而每單位平均銷售價格上漲20％。
截至6月30日的三個月和六個月的毛利潤分別爲30,000和197,000美元，毛利率從32％提高到了42％。
2024年第二季度淨虧損爲130萬美元，較2023年虧損210萬美元有所改善。
截至2024年6月30日，該公司的現金餘額爲370萬美元，而2023年底爲340萬美元。
Business Progress:
業務進展：
Tivic Health has made significant progress in the development of a noninvasive vagus nerve stimulation (VNS) system, in collaboration with the Feinstein Institutes for Bioelectronic Medicine.
The company completed Phase 1 trials showing profound biological effects, promising for the treatment of neurological, cardiovascular, and autonomic system diseases.
Tivic Health在與Feinstein Institutes for Bioelectronic Medicine合作的非侵入性迷走神經刺激（VNS）系統的開發方面取得了重大進展。
該公司完成了第一階段試驗，表現出深刻的生物效應，有望治療神經系統、心血管系統和自主神經系統疾病。
Opportunities:
機會：
The new noninvasive VNS system represents a high-value medical target with potential to generate stronger shareholder returns.
Tivic's noninvasive bioelectronic platforms offer significant market differentiation and potential premium pricing, responding to unmet needs in medical-grade noninvasive VNS devices.
The company is exploring alternative monetization strategies for the ClearUP product.
新的非侵入性VNS系統代表着一個高價值的醫療目標，有可能帶來更強的股東回報。
Tivic的非侵入式生物電平台爲醫用非侵入式VNS設備的未滿足需求提供了明顯的市場差異化和潛在溢價定價。
該公司正在探索ClearUP產品的替代變現策略。
Risks:
風險：
Tivic faces risks from operational cutbacks possibly impacting their ability to support new scientific advancements.
Threat of non-compliance with NASDAQ's $1.00 per share minimum bid price requirement, though they have until December 26 to regain compliance.
Tivic面臨着運營裁員可能影響其支持新科學進展能力的風險。
儘管該公司有時間到12月26日恢復遵守納斯達克的每股最低買入價格要求，但面臨不遵守的威脅。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
